Skip to content

Study · Not a test of the peptide alone · 2006

5 results

Overexpression of thymosin beta-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively.

Hsiao HL, Wang WS, Chen PM, Su Y

Carcinogenesis19 Dec 2005Cited by 22 (Europe PMC)

PMID16364925 (opens in a new tab)DOI10.1093/carcin/bgi316 (opens in a new tab)PepBankPUB-16364925
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    In SW480 colon cancer cells, Tbeta4 overexpression made the cells more resistant to killing by FasL-bearing Jurkat T cells.

    In plain wordsIn cells, extra Tbeta4 made colon cancer cells more resistant to killing by T cells than control cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseResistance to killing by FasL-bearing Jurkat T cells
    Study

    humann: not reported in source

    SW480 colon carcinoma cells overexpressing Tbeta4
    Comparator
    Control SW480 cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    As expected, Tbeta4 overexpressers were also more resistant to the killing effect of FasL-bearing Jurkat T cells.
    1 context sentence
    Summary · context
    The present work was conducted to further examine the effects of thymosin beta-4 (Tbeta4) upregulation on the apoptosis of SW480 colon cancer cells induced by T cells and various chemotherapeutic agents because reduced susceptibility to the cytotoxicity of an anti-Fas IgM (CH-11) in Tbeta4-overexpre…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In Tbeta4-overexpressing SW480 cells, pretreatment with an MMP inhibitor restored Fas levels and sensitivity to CH-11.

    In plain wordsIn cells, blocking MMP restored Fas levels and sensitivity to an anti-Fas antibody in Tbeta4-overexpressing colon cancer cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseFas level and CH-11 sensitivity after MMP inhibitor
    Study

    humann: not reported in source

    SW480 colon carcinoma cells overexpressing Tbeta4
    Comparator
    Untreated Tbeta4 overexpressers
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    On the other hand, pretreating these cells with an MMP inhibitor restored not only their Fas levels but also their sensitivity to CH-11, suggesting a pivotal role of MMP in downregulating Fas in Tbeta4 overexpressers.
    1 context sentence
    Summary · context
    The present work was conducted to further examine the effects of thymosin beta-4 (Tbeta4) upregulation on the apoptosis of SW480 colon cancer cells induced by T cells and various chemotherapeutic agents because reduced susceptibility to the cytotoxicity of an anti-Fas IgM (CH-11) in Tbeta4-overexpre…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    In SW480 cells, Tbeta4 overexpression did not change susceptibility to 5-FU or irinotecan.

    In plain wordsIn cells, extra Tbeta4 did not change how colon cancer cells responded to 5-FU or irinotecan.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeSusceptibility to 5-FU and irinotecan
    Study

    humann: not reported in source

    SW480 colon carcinoma cells overexpressing Tbeta4
    Comparator
    Control SW480 cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    while the susceptibilities of Tbeta4 overexpressers to 5-FU and irinotecan remained unchanged
    1 context sentence
    Summary · context
    The present work was conducted to further examine the effects of thymosin beta-4 (Tbeta4) upregulation on the apoptosis of SW480 colon cancer cells induced by T cells and various chemotherapeutic agents because reduced susceptibility to the cytotoxicity of an anti-Fas IgM (CH-11) in Tbeta4-overexpre…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    In SW480 cells, Tbeta4 overexpression increased resistance to doxorubicin and etoposide, which trigger apoptosis through a mitochondrial pathway.

    In plain wordsIn cells, extra Tbeta4 made colon cancer cells more resistant to doxorubicin and etoposide than control cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseResistance to doxorubicin and etoposide
    Study

    humann: not reported in source

    SW480 colon carcinoma cells overexpressing Tbeta4
    Comparator
    Control SW480 cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    they were more resistant to doxorubicin and etoposide which triggered apoptosis via a mitochondrial pathway.
    1 context sentence
    Summary · context
    The present work was conducted to further examine the effects of thymosin beta-4 (Tbeta4) upregulation on the apoptosis of SW480 colon cancer cells induced by T cells and various chemotherapeutic agents because reduced susceptibility to the cytotoxicity of an anti-Fas IgM (CH-11) in Tbeta4-overexpre…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  5. 05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In SW480 cells, Tbeta4 overexpression strongly reduced caspase 9 and 3 activation by two topoisomerase II inhibitors, linked mainly to higher Survivin expression.

    In plain wordsIn cells, extra Tbeta4 sharply reduced caspase activation by two chemotherapy drugs, linked mainly to more Survivin.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseCaspase 9 and 3 activation by topoisomerase II inhibitors
    Study

    humann: not reported in source

    SW480 colon carcinoma cells overexpressing Tbeta4
    Comparator
    Control SW480 cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Concordantly, activation of both caspases 9 and 3 in Tbeta4 overexpressers by the two aforementioned topoisomerase II inhibitors was dramatically abrogated which could be accounted mainly by an increased expression of Survivin, a critical anti-apoptotic factor.
    1 context sentence
    Summary · context
    The present work was conducted to further examine the effects of thymosin beta-4 (Tbeta4) upregulation on the apoptosis of SW480 colon cancer cells induced by T cells and various chemotherapeutic agents because reduced susceptibility to the cytotoxicity of an anti-Fas IgM (CH-11) in Tbeta4-overexpre…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.